Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy by Baida, Gleb et al.
Oncotarget34772www.oncotarget.com
Deletion of the glucocorticoid receptor chaperone FKBP51 
prevents glucocorticoid-induced skin atrophy
Gleb Baida1, Pankaj Bhalla1, Alexander Yemelyanov2, Lance A. Stechschulte3, 
Weinian Shou4, Ben Readhead5,6, Joel T. Dudley5,6, Edwin R. Sánchez3 and Irina 
Budunova1
1Department of Dermatology, Northwestern University, Chicago, IL, USA
2Department of Medicine, Pulmonary Division, Northwestern University, Chicago, IL, USA
3Department of Physiology & Pharmacology, The Center for Diabetes and Endocrine Research, University of Toledo College 
of Medicine, Toledo, OH, USA
4Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
5Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
6Institute for Next Generation Healthcare, Mount Sinai Health System, New York, NY, USA
Correspondence to: Irina Budunova, email: i-budunova@northwestern.edu
Keywords: glucocorticoid; glucocorticoid receptor; skin atrophy; FKBP51; Akt
Received: July 27, 2018    Accepted: September 15, 2018    Published: October 05, 2018
Copyright: Baida et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
FKBP51 (FK506-binding protein 51) is a known co-chaperone and regulator of the 
glucocorticoid receptor (GR), which usually attenuates its activity. FKBP51 is one of 
the major GR target genes in skin, but its role in clinical effects of glucocorticoids is not 
known. Here, we used FKBP51 knockout (KO) mice to determine FKBP51’s role in the 
major adverse effect of topical glucocorticoids, skin atrophy. Unexpectedly, we found 
that all skin compartments (epidermis, dermis, dermal adipose and CD34+ stem cells) 
in FKBP51 KO animals were much more resistant to glucocorticoid-induced hypoplasia. 
Furthermore, despite the absence of inhibitory FKBP51, the basal level of expression 
and glucocorticoid activation of GR target genes were not increased in FKBP51 KO skin 
or CRISPR/Cas9-edited FKBP51 KO HaCaT human keratinocytes. FKBP51 is known to 
negatively regulate Akt and mTOR. We found a significant increase in AktSer473 and 
mTORSer2448 phosphorylation and downstream pro-growth signaling in FKBP51-
deficient keratinocytes in vivo and in vitro. As Akt/mTOR-GR crosstalk is usually 
negative in skin, our results suggest that Akt/mTOR activation could be responsible 
for the lack of increased GR function and resistance of FKBP51 KO mice to the steroid-
induced skin atrophy.
INTRODUCTION
Glucocorticoid hormones (Gcs) are steroid 
hormones mostly produced in the adrenal cortex. 
However, they can be also synthesized locally in different 
tissues including skin which expresses the genes for 
enzymes involved in glucocorticoid biosynthesis [1–3]. 
Gcs are well known physiological and pharmacological 
regulators of metabolism, proliferation, differentiation 
and inflammation in skin [4], and the decreased amount of 
endogenous Gcs in skin is now linked to the skin diseases 
such as psoriasis [5].
The synthetic Gcs were introduced as potent anti-
inflammatory drugs in 1950-s, and remain the frontline 
for the treatment of inflammatory skin diseases, including 
psoriasis and atopic dermatitis [6, 7]. Unfortunately, 
chronic treatment with Gcs induces numerous adverse 
effects including cutaneous atrophy, which involves all 
skin compartments and results in overall skin thinning, 
reduction in size and number of keratinocytes, inhibition 
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of dermal fibroblast proliferation and collagen synthesis, 
and atrophy of sebaceous glands, hair follicles and dermal 
adipose [8–10]. Although these morphological changes are 
well documented, the molecular mechanisms underlying 
development of skin atrophy are not well understood.
The effects of glucocorticoids are mediated by 
the glucocorticoid receptor (GR), a well-characterized 
transcription factor and member of the nuclear receptor 
family. In unstimulated cells, GR resides in cytoplasm 
bound to chaperones including heat shock proteins and 
immunophilins, such as FKBP51 (FK506-binding protein 
51), which control GR activation and nuclear import [11]. 
Upon hormone binding, GR translocates to the nucleus 
where it regulates gene expression positively via binding 
to glucocorticoid response elements of target genes; or 
negatively via different mechanisms, including tethering 
– binding to other transcription factors, such as NF-κB, to 
modulate their activity [11]. In addition, GR can modulate 
in DNA-binding independent manner the pro-proliferative/
pro-survival signaling mediated by phosphatidylinositol 
3-kinase (PI3K), Akt, mTOR, and mitogen-activated 
protein kinases (MAPKs) [11–13].
We and others found that FKBP51 is a major 
GR target gene in skin, as it was strongly up-regulated 
in keratinocytes of skin-specific keratin5 (K5)-GR 
transgenics and down-regulated in GR knockout (KO) 
mice [14, 15]. FKBP51 is a member of FK506-binding 
protein (Fkbp) family. Like all immunophilins, FKBP51 
has peptidyl-prolyl isomerase (PPIase) activity and 
is involved in immunoregulation, protein folding and 
trafficking [16]. As a molecular chaperone, FKBP51 has 
numerous clients including steroid receptors. In the case 
of GR, interaction with FKBP51 interferes with receptor 
maturation, reduces ligand-binding affinity and impairs 
GR nuclear import [17, 18]. Binding of ligand to GR 
favors replacement of FKBP51 with FKBP52, which then 
increases GR affinity to glucocorticoids, dimerization and 
nuclear transport [19].
FKBP51 is also known to control Akt, mTOR, and 
NF-κB pathways that in turn, negatively crosstalk with 
GR. Growth factor-dependent, full Akt activation requires 
phosphorylation at Thr308 and Ser473 [20]. FKBP51 
acts as a scaffolding protein to enhance the interaction 
of the phosphatases PHLPP1/2 with Akt, which results 
in dephosphorylation of Ser473 [21, 22]. FKBP51 also 
binds to mTOR and inhibits its kinase activity as potently 
as rapamycin with its accessory partner FKBP12 [23]. 
In addition, FKBP51 impairs both NF-κB’s nuclear 
translocation and transcriptional activity [24, 25]. The 
role of FKBP51 in the effects of topical glucocorticoids 
in skin has not been studied. Here, we confirmed FKBP51 
induction by glucocorticoids in mouse and human skin, 
and used FKBP51 KO mice [26] to determine the role of 
FKBP51 in glucocorticoid-induced skin atrophy.
As FKBP51 is a major negative GR regulator, 
the possible outcomes in FKBP51 KO animals could 
be elevated GR activity and enhanced anti-proliferative 
effects of endogenous/exogenous glucocorticoids. 
However, we found that FKBP51 KO mice had modest 
epidermal hyperplasia and were much more resistant 
to skin atrophy induced by chronic treatment with the 
glucocorticoid fluocinolone acetonide (FA) than wild type 
mice. This effect in FKBP51 KO mice was seen despite 
the lack of changes in GR activity. We also found that Akt 
and mTOR were constitutively activated in FKBP51 KO 
skin and in HaCaT human keratinocytes lacking FKBP51. 
Taken as a whole, our results suggest that FKBP51 acts as 
an atrophogene during chronic skin treatment with steroids 
in part by inhibiting Akt/mTOR activity.
RESULTS
Topical glucocorticoids induce FKBP51 
expression
FKBP51 is a GR target gene [14, 15]. However, the 
effect of glucocorticoids on FKBP51 in skin has not been 
well studied. We used a medium potency glucocorticoid 
fluocinolone acetonide (FA) to topically treat wild type 
F1 C57Bl x 129 mice, and a highly potent glucocorticoid 
clobetasol propionate (CBP) to treat human volunteers. 
The glucocorticoid doses and regimens used induce 
significant mouse and human skin atrophy, as shown 
previously [14, 27].
In mouse and human skin, the basal level of 
FKBP51 expression in epidermis and skin appendages 
was low (Figure 1). In mice, FKBP51 expression was 
strongly induced at mRNA and protein levels 8 h after 
FA application, and remained elevated during 2 wk 
treatment (Figure 1a-1c). FKBP51 protein was expressed 
in interfollicular epidermis, hair follicles and sebaceous 
glands in FA-treated skin (Figure 1c). Glucocorticoids-
induced hypoplastic changes in mouse epidermis are 
always paralleled by the severe atrophy of dermal adipose 
[27], (Figure 2). Thus, we assessed FKBP51 expression 
in subcutaneous adipose mechanically separated from 
other skin tissues. The purity of adipose isolations was 
verified using specific adipocyte and keratinocyte markers 
(Supplementary Figure 1). We found strong, comparable 
to epidermis, induction of FKBP51 mRNA in adipose 
(Figure 1b).
To complement the animal study, we assessed the 
effect of glucocorticoid CBP on FKBP51 in human skin. 
We detected strong induction of FKBP51 mRNA and 
protein in human skin 24 h after CBP application (Figure 
1d, 1e).
Skin phenotype of FKBP51 KO mice
To determine the role of FKBP51 in glucocorticoid-
induced skin atrophy, we used FKBP51 KO mice (Bl x 
129 genetic background) that have no overt phenotype 
Oncotarget34774www.oncotarget.com
if untreated [26]. Interestingly, FKBP51 KO mouse 
skin was characterized by a modest, but significant, 
epidermal hyperplasia (Supplementary Figure 2a, 2c, 
2d) and increased keratinocyte proliferation. In non-
treated females the BrdU+ labeling indices were 4.2%+/-
1.6 and 6.25%+/-2.5 in WT and FKBP51 KO mice 
accordingly (t-statistic, P<0.001). In males, there was 
also a trend to the increase in BrdU index in FKBP51 KO 
animals: 4.3% ± 1.5 in FKBP51 KO versus 2.7% ± 1.5 
in WT epidermis (t-statistic, P=0.065). We also observed 
alteration of hair follicle morphology – unusual dilation 
of infundibulum frequently filled with flocculent mixture, 
especially in males (Supplementary Figure 2a, 2e). At the 
same time, there were no changes in the expression of 
keratinocyte differentiation markers K5, K10 and loricrin 
(Supplementary Figure 2b), suggesting that FKBP51 is 
involved in keratinocyte proliferation but not required for 
normal keratinocyte differentiation.
Resistance of FKBP51 KO mice to 
glucocorticoid-induced skin atrophy
FKBP51 is a negative GR regulator, thus we 
expected that FKBP51 KO animals would be much more 
sensitive to the effects of glucocorticoids. Unexpectedly, 
FKBP51 KO mice appeared more resistant to skin atrophy 
than WT mice when subjected to FA chronic treatment. 
Epidermal thickness was reduced much less in both female 
and male KOs (by 16-22%) compared to WT mice (by 
40-45%) (t-statistic, P<0.001; Figure 2a, 2d). In addition, 
dermal adipose was very strongly protected in the 
FKBP51 KO animals, especially in males. In females, the 
dermal adipose thickness was reduced at the end of two 
week FA treatment by 90% in WT compared to 60% in 
FKBP51 KO animals (Supplementary Figure 4). In males, 
the protective effect was even more pronounced: dermal 
adipose thickness was reduced in FA-treated WT skin 
by 80% while in FKBP51 KOs only by 10% (t-statistic 
P<0.001; Supplementary Figure 4). Interestingly, these 
results differed from our previous observations that 
FKBP51 positively controls adipogenesis in vitro, and in 
gonadal fat depot in vivo [28, 29].
Previously we found that GR activation sharply 
reduced the number and proliferative potential of 
epidermal stem cells (SCs) in the hair follicle bulge niche 
[14, 30]. Here, WT mice chronically treated with FA also 
showed almost a complete elimination of CD34+ follicular 
SCs (Figure 2c). Remarkably, in FKBP51 KO mice, 
the effect of FA on CD34 expression in the bulge was 
diminished, and ~ 25% of hair follicles remained CD34+ 
(Figure 2c), suggesting that the persistence of bulge SCs 
may have contributed to the protection of epidermis in KO 
mice against steroid atrophy.
The major atrophic effects of topical steroids in 
dermis include severe thinning of collagen and elastin 
fibrous networks and decreased dermal cellularity [10]. 
Masson’s trichrome staining, which colors collagen blue, 
showed strongly reduced collagen fiber density in WT 
mice in contrast to FKBP51 KOs where effects on fiber 
network and dermal fibroblasts were minimal (Figure 2b).
Figure 1: Induction of FKBP51 expression in the skin by glucocorticoids. F1 C57Bl x 129 WT mice were treated topically with 
acetone (vehicle control, C) or glucocorticoid FA (2 μg/animal, for 8 h, 24 h or 2 wk). Skin of the inner upper arm of human volunteers was 
treated topically with 0.05% CPB cream once for 24 h; untreated skin from the opposite arm was used as control (C). FKBP51 expression 
was analyzed by qPCR and by Western blotting (WB) in murine epidermis (a), by RT-PCR in epidermis and subcutaneous (s.c.) fat of 
mice (b), or in whole thickness human skin biopsies (d); Rpl27 was used as normalization/loading control. FKBP51 immunostaining of 
mouse (c) and human (e) skin. Scale bars are 20 μm (c) and 40 μm (e). * P < 0.01, (unpaired two-tailed t-test) for changes compared to 
corresponding control.
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It is known that genetic background can significantly 
affect phenotype of transgenic animals. Thus, we assessed 
the effect of FKBP51 KO on steroid skin atrophy using 
FKBP51 KO animals in C57Bl background. We found 
that FKBP51 KO provided even stronger protection 
against steroid-induced epidermal atrophy in C57Bl mice 
(Supplementary Figure 3).
Effect of FKBP51 KO on GR activity and 
mTOR/Akt phosphorylation in skin
The reduced sensitivity of FKBP51 KO mice 
to glucocorticoid skin atrophy suggested that lack of 
FKBP51 could affect GR expression/signaling. We 
did not find significant changes in GR protein levels in 
epidermis of untreated FKBP51 KOs (Figure 3a). To 
assess changes in GR activity, we measured basal and FA-
induced expression of known GR-target genes Tsc22d3/
Gilz, Ddit4/Redd1, Cyp2b10, Txnip, Hmgcs2, and Tppp3, 
[27, 31–33], which were also revealed previously among 
the differentially expressed genes in skin of B6x129 WT 
mice treated with FA (our GEO Submission GSE59151). 
Surprisingly, despite the absence of inhibitory FKBP51, 
the glucocorticoid activation of these genes in KO mice 
was similar to that seen in WT epidermis (Figure 3e).
Other mechanisms by which FKBP51 could 
modulate GR signaling are through the inhibition of Akt, 
mTOR and/or NF-κB pathways [19, 20, 25], all of which 
negatively interact with GR signaling at different levels 
[11–13]. FKBP51 deficiency did not result in significant 
changes in the expression and phosphorylation of RelA/
p65, the major NF-κB protein in mouse skin (data not 
shown). In contrast, we found strongly increased AktSer473 
phosphorylation in the epidermis and appendages of 
Figure 2: Resistance of FKBP51 KO mice to glucocorticoid-induced skin atrophy. WT and FKBP51 KO male and female mice 
were treated with vehicle (Control) and FA (2 μg/animal) for 2 wks. (a) H&E; (b) Masson’s trichrome staining; (c) CD34 immunostaining. 
Epidermis (green arrows), dermal adipose layer (A), dermis (D) and hair follicle bulge regions (HF bulge) are marked. Scale bars are 20 μm 
(a, b) and 10 μm (c). (d) Quantitation of the epidermal thickness in female and male WT and FKBP51 KO mice was performed as described 
in Materials and Methods. Epidermal thickness is presented as % to corresponding control epidermis. The means ± SD were calculated 
for three individual skin samples in one representative experiment. ** P < 0.001, (unpaired two-tailed t-test) for changes compared to 
corresponding control. # P < 0.001, (unpaired two-tailed t-test) for degree of reduction in epidermal thickness in FKBP51 KO animals 
compared to WT animals.
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vehicle- and FA-treated FKBP51 KO compared to WT 
mice, along with increased phosphorylation of mTORSer2448 
(Figure 3c, 3d), the site targeted by Akt and mTOR 
effector ribosomal p70/S6 kinase1 (S6K1) [34–36]. 
These results are in agreement with our previous report 
on the Akt activation in FKBP51 KO murine fibroblasts 
[37]. We confirmed Akt and mTOR activation and their 
partial resistance to inhibitory effects of glucocorticoid 
FA in the skin of Fkbp51 KO animals using Western blot 
analysis (Figure 3b). Akt activity was assessed by AktSer473 
phosphorylation, and mTOR activity - by phosphorylation 
of major mTOR downstream substrate 4E-BP1with easily 
detectable basal phosphorylation level in skin [38]. 
Surprisingly, we observed that in FKBP51 KO mice 
AktSer473 phosphorylation was increased by FA at earlier 
time-point of treatment.
Figure 3: Effects of FKBP51 KO on GR function and Akt/mTOR phosphorylation in murine skin. (a) Western blot (WB) 
analysis of GR expression in untreated C57Blx129 wild type (WT) and FKBP51 KO murine epidermis (two individual samples/condition). 
Actin was used as a loading control. (b) Western blot analysis of expression of phospho-AktSer473 and phospho-4E-BP1Thr37/46 in WT and 
FKBP51 KO murine epidermis treated with FA once for 24 h (1xFA) or four times during 2 weeks (4xFA) as described in Materials and 
Methods. Tubulin (T) was used as a loading control. ImageJ was used for densitometry. The intensity of p-Akt and p-4E-BP1 bands was 
normalized to the corresponding loading control (T) and expressed as fold of change vs vehicle-treated WT control. (c, d) Immunostaining 
for phospho-AktSer473 (c) and phospho-mTORSer2448 (d) in murine skin. Scale bars, 20 μm. (e) qPCR analyses of GR target genes expression 
in epidermis. Gene induction is fold change in expression after FA x 24 h (+) versus basal (-) expression in the same genotype. The results 
(normalized to Rpl27) are the means ± SD calculated for three individual RNA samples/condition. * P<0.05, (unpaired two-tailed t-test) 
for changes compared to corresponding control. NS - nonsignificant difference in FA-induction between WT and FKBP51 KO animals.
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Effects of FKBP51 knockout on GR and Akt/
mTOR function in human keratinocytes in vitro
To extend our findings and determine whether 
FKBP51 deficiency affects major steps of GR activation 
such as phosphorylation and nuclear import/retention, we 
generated FKBP51 KO keratinocytes using CRISPR/Cas9 
technology. Nontumorigenic human HaCaT keratinocytes 
were transiently transfected with gRNAs in a complex 
with recombinant Cas9 to knockdown FKBP51 expression 
(FKBP51 KO-HaCaT). Control cells were transfected with 
Cas9 only (Figure 4a). Two FKBP51 KO-HaCaT cell lines 
were established from single cell clones, and used for 
experiments.
The results of Figure 4b show that loss of 
FKBP51 did not affect the amount of GR or its ability to 
translocate to the nucleus in response to glucocorticoid 
FA. Moreover, FA-induced GR phosphorylation at 
activating Ser211 and nuclear translocation/retention 
of phosphorylated GR were similar in FKBP51 KO-
HaCaT and control HaCaT keratinocytes. We also did 
not find significant changes in activation of known GR 
target genes DDIT4/REDD1, KLF9, BEST2, TFCP2L1, 
and TSC22D3/GILZ [27, 30-32, 38] in FKBP51 KO 
keratinocytes (Figure 4d). These specific GR target 
genes were selected from the list of differentially 
expressed genes in HaCaT cells treated with FA (our 
GEO submission GSE97279, [38]).
In good correlation with in vivo results, we observed 
increased activation of Akt and mTOR after FKBP51 
KO in HaCaT cells as assessed by phosphorylation of 
AktSer473, mTORSer2448, and mTOR effector ribosomal p70/
S6 kinase1Thr389 (Figure 4b). At the same time, FKBP51 
knockdown in HaCaT cells did not affect NF-kB function 
monitored by NF-kB protein RelA/p65 phosphorylation 
and nuclear translocation activated by TNF-a (Figure 4c).
DISCUSSION
Glucocorticoid-induced skin atrophy represents a 
serious clinical problem as it leads to debilitating cosmetic 
effects and compromised skin barrier function [6]. The 
focus of this study was on the search for the molecular 
mechanisms underlying skin atrophy. We report here 
that the induction of FKBP51, a GR target gene involved 
in negative feedback loop in GR signaling, coincided 
with the development of cutaneous atrophy in humans 
and mice. Using FKBP51 KO mice, we discovered that 
FKBP51 acts as atrophogene, as in its absence all skin 
compartments and epidermal follicular SCs became 
protected from the hypoplastic effects of glucocorticoids.
The resistance of FKBP51 KO mice to steroid-
induced skin atrophy was unexpected as FKBP51 is 
generally thought to be a negative regulator of GR activity 
[16, 17]. As a molecular chaperone that binds GR/Hsp90 
heterocomplexes, FKBP51 has been shown to reduce GR 
affinity for ligands, to interfere with nuclear localization 
of receptor complexes under hormone-free conditions, 
and to alter GR phosphorylation [16, 18]. In light of 
these data, the lack of changes in GR phosphorylation at 
activating Ser211 in FKBP51 KO HaCaT keratinocytes 
was surprising. Equally unexpected was the lack of 
increased GR function in skin of FKBP51 KO mice and in 
keratinocytes after FKBP51 knockout suggesting that the 
concept of FKBP51 as a global negative regulator of GR 
should be revisited.
FKBP51 is a multi-functional protein: in addition 
to chaperoning steroid receptors, it negatively regulates 
activity of other signaling pathways such as Akt and 
mTOR, critical for protein synthesis and cell proliferation 
[19]. We report here that the levels of phospho-AktSer473, 
phospho-mTORSer2448 and phosphorylated downstream 
mTOR pro-proliferative effectors S6K1 and rpS6 were 
elevated in human keratinocytes lacking FKBP51 in vitro 
and in FKBP51 KO mouse skin in vivo.
The negative cross-talk between anabolic mTOR/
Akt and catabolic GR signaling and inhibition of GR 
function by mTOR are well known in different tissues 
including muscle [13]. We recently showed that GR 
function is impaired in skin lacking mTOR/Akt inhibitor 
DDIT4/REDD1 [27]. The inhibitory effect of mTOR/Akt 
on GR could be mediated via direct phosphorylation of GR 
at Ser134, which negatively regulates GR activity [39]. 
Thus, increased activation of Akt/mTOR pro-metabolic/ 
pro-proliferative signaling may help to explain the lack 
of GR activation as well as the protection of CD34+ stem 
cells, keratinocytes, dermal fibroblasts and adipocytes 
from glucocorticoids in FKBP51 KO mice.
Importantly, despite the increased activity of pro-
proliferative Akt/mTOR signaling in the skin of FKBP51 
KO mice, we observed only mild skin hyperplasia in 
these animals, and neither young nor aged FKBP51 
KOs developed any cutaneous cancer lesions (data not 
shown). It is known that FKBP51 plays the important 
tissue-specific role in cancer development, and in skin 
it positively regulates melanoma stemness, growth, 
and metastatic potential [40–41]. However, its role 
in non-melanoma skin carcinogenesis remains to be 
investigated.
Interestingly, we identified recently another major 
target of glucocorticoids/GR, DDIT4/REDD1 (regulated 
in development and DNA damage response 1), as an 
atrophogene in skin [27, 38]. Like FKBP51, REDD1 
is also a negative regulator of mTOR/Akt signaling 
[42, 43], and its genetic or pharmacological blockage 
spared skin from steroid-induced atrophy [27, 38]. Here 
we show that GR-mediated expression of REDD1 was 
unchanged in FKBP51 KO keratinocytes suggesting that 
down-regulation of FKBP51 alone is sufficient for partial 
resistance of skin to steroid-induced atrophy.
Overall, our studies highlight the complex, 
cell context-dependent regulation of GR function by 
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Figure 4: Effect of FKBP51 KO on glucocorticoid response and Akt/mTOR in HaCaT human keratinocytes. FKBP51 
KO and Cas9 (control) HaCaT human keratinocytes were treated with glucocorticoid FA (10-6 M) or vehicle as indicated. (a) Verification 
of FKBP51 knockout by Western blotting (WB), two independent FKBP51 KO clones (L1, L2) tested. GAPDH, loading control. (b, c) 
Western blot analyses for expression, phosphorylation, and subcellular localization of GR, Akt, mTOR, p70/S6K1, and NF-kB p65 in cells 
treated with FA (10-6 M x 0 (untreated), 1 h, and 4 h) (b); or with TNF-a (50 μg/ml x 20 min) (c). Nuclear (NF) and cytosol (CF) fractions 
were isolated as in Materials and Methods. Lamin and tubulin were used as nuclear and cytoplasmic loading controls, respectively. ImageJ 
was used for densitometry. For phosphorylated and total GR and p65, the intensity of bands was normalized to the corresponding loading 
controls and expressed as folds of change to vehicle-treated Cas9-HaCaT. For AKT, mTOR, and p70, the ratios of phosphorylation are 
expressed as folds of change to vehicle-treated Cas9-HaCaT. (d) qPCR analysis of GR target genes in cells treated with FA (10-6 M) for 24 
h. The results (normalized to Rpl27) are the means ± SD calculated for three individual RNA samples/condition. Gene induction is fold of 
change in expression after FA (+) versus basal (-) expression. * P < 0.05 (unpaired two-tailed t-test) for changes compared to corresponding 
control. NS - nonsignificant difference in FA-induction between Cas9- and FKBP51 KO HaCaT cells.
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FKBP51. Our results also imply that targeting of GR–
dependent genes causatively involved in skin atrophy, 
such as FKBP51, could be a potential strategy to reduce/
alleviate glucocorticoid-associated skin atrophy in the 
clinic.
Taking into consideration the potential anti-cancer 
effect of FKBP51 inhibition in skin [40] and similarity 
between atrophic processes in aged skin and skin 
chronically treated with glucocorticoids [44, 45], the same 
strategy could be relevant to a safe skin protection against 
aging. Importantly, FKBP51 belongs to the group of the 
genes whose expression in skin depends on age [46]. Since 
FKBP51 has been implicated in different neurological 
disorders, including post-traumatic stress disorder and 
Alzheimer’s disease [18], efforts are already underway to 
develop FKBP51-specific inhibitors [47–48].
MATERIALS AND METHODS
Chemicals
FA and all other chemicals unless stated otherwise 
were purchased from Sigma (St. Louis, MO). CBP (0.05% 
cream) was purchased at the pharmacy.
Animals and treatments
B6x129 (F1 C57BL/6 X 129SvEv) and C57Bl/6 
wild-type (WT) mice were from Taconic (Germantown, 
NY). FKBP51 KO mice on B6x129 genetic background 
were generated by an insertional mutation in intron 4 of 
the Fbkp5 gene [26]. Later transgene was transferred into 
C57Bl/6 genetic background. Seven-wk old mice were 
shaved and treated 3 days later. FA was applied topically (2 
μg/200 μl acetone) to the back skin once or 4 times every 
third day for two weeks as described [14]. Control animals 
were treated with acetone only. Skin was harvested 4-24 h 
after the last application as indicated in the Figure legends. 
Mice were injected ip with BrdU (50 μg/g body weight) 1 
h before sacrifice. For biochemical studies, epidermis and 
subcutaneous fat were mechanically isolated from the skin 
by scraping [14].
All animal experiments were approved by the 
Northwestern University Animal Care and Use Committee.
Human volunteers
CBP cream (0.05%) was applied topically to 
the inner skin of the upper right arm of healthy human 
volunteers (age 32-45) once. Untreated left arm skin 
was used as control. Five mm punch skin biopsies were 
taken 24 h after CBP application and processed for RNA 
extraction or formalin-fixed for immunohistochemistry. All 
human studies were approved by Northwestern University 
Institutional Review Board. Written informed consent was 
received from the volunteers before participation.
Human keratinocyte cell cultures
HaCaT human keratinocyte cells are in vitro 
spontaneously-immortalized keratinocytes from 
histologically normal human skin [49]. Cells were kindly 
provided by Dr. K. Green (Northwestern University, 
Chicago). HaCaT cells were cultured in Dulbecco's 
Modified Eagle medium containing 10% FBS (Cellgro; 
Manassas, VA) and antibiotics.
Knockout of FKBP51 expression by CRISPR/
Cas9 gene-editing
CRISPR/Cas9 gene-editing was used to ablate 
FKBP51 in HaCaT cells. Recombinant Cas9 protein 
and CRISPR crRNA were purchased from Integrated 
DNA Technologies (Coralville, IA). The gRNAs were 
designed using publicly accessible engines (http://
crispr.mit.edu/; http://chopchop.cbu.uib.no/ (http://
www.uib.no/en/persons/) as described [50–52]. 
Only top ranked gRNA with no off-target effects 
confirmed by two design sites were selected for the 
knock-out procedure (gRNA1, FKBP51 exon 2, 
ATTACCTCCAAAAAAGACAG; gRNA2, FKBP51 
Exon 3, GGTGAGGAAACGCCGATGAT; gRNA3, 
FKBP51 Exon 4, GTCATCAAGGCATGGGACAT). 
HaCaT cells were transiently transfected with 
ribonucleoprotein complex (RNPC) using RNAi-Max 
transfection reagent (Fisher Scientific). The advantages of 
RNPC (with Cas9 protein and synthetic gRNAs) versus 
standard vector-based CRISPR approaches include rapid 
RNPC degradation after gene editing resulting in minimal 
Cas9-gRNA off-target effects and cytotoxicity. Single-
cell colonies were established from CRISPR-edited 
cell cultures and analyzed by sequencing and Western 
blotting to verify the knock-out of FKBP51 gene. Cas9-
only-treated cells were used as a control. Experiments 
were performed in two different FKBP51 KO clones 
(L1 and L2).
Histological analysis and immunostaining
Formalin-fixed, paraffin-embedded skin sections 
were stained with hematoxylin and eosin (H&E) and/
or antibodies against BrdU (BD Biosciences; San Jose, 
CA), keratinocyte differentiation markers keratins 5 and 
10 and loricrin (Covance; Greenfield, IN), FKBP51 and 
GR (Santa Cruz; Dallas, TX), phospho-mTORSer2448, 
phospho-AktSer473 (Cell Signaling; Danvers, MA), stem cell 
marker CD34 (Abcam; Cambridge, MA) and Masson’s 
trichrome to assess dermal collagen density/organization.
Quantification of the epidermal and dermal 
adipose thicknesses (as the readouts for skin thinning) 
was performed in H&E stained skin sections. At least 
10 individual fields/slide in three individual samples/
experimental group were counted using Axioplan2 
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microscope software (Carl Zeiss). To assess keratinocyte 
proliferation, the number of proliferating (BrdU+) and total 
basal keratinocytes was counted in 10 individual fields/
slide of each sample.
To assess the effect of FA on the expression of CD34 
stem cell marker, we examined ~ 100 hair follicles in the 
skin samples of each genotype (3 individual skin samples/
group). Hair follicles with ≥5 CD34+ cells in the bulge, 
were considered positive.
Western blot analysis
Whole cell protein extracts were prepared as 
described [27]. Separate cytoplasmic and nuclear protein 
fractions were isolated with NE-PER Nuclear and 
Cytoplasmic Extraction Kit according to manufacturer 
protocol (ThermoFisher Scientific, Waltham, MA). The 
proteins were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes (LI-COR Biosciences; Lincoln, 
NE). After blocking, membranes were incubated with 
primary antibodies overnight at 4°C, followed by IRDye® 
secondary antibodies (LI-COR Biosciences). LI-COR 
Odyssey Imager was used for the band visualization. The 
antibodies against FKBP51, GR, RelA/p65, p65Ser536 (Santa 
Cruz Biotechnology, Dallas, TX), Redd1 (Proteintech; 
Chicago, IL), phospho-GRSer211, Akt, phospho-AktSer473, 
phospho-rpS6Ser240/244, phospho-p70/S6KThr389, lamin B, 
tubulin (Cell Signaling, Danvers, MA), and GAPDH 
(Sigma, St Louis, MO) were used at concentrations 
recommended by their manufacturers. The multi-band 
pattern of FKBP51 signal on Western blots (Figure 1a) 
may reflect FKBP51 post-translational modifications such 
as phosphorylation [41].
ImageJ (http://rsb.info.nih.gov/ij/index.html) 
was used for densitometry. The intensity of bands was 
normalized to the corresponding loading control and 
expressed as fold of change vs vehicle-treated WT or 
Cas9-only control.
RNA preparation and PCR
RNA from whole human skin, murine epidermis 
and keratinocyte cultures were isolated with RiboPure 
kit (Ambion/Life Technologies; Grand Island, NY), 
and from subcutaneous adipose with RNeasy Lipid 
Tissue Kit (Qiagen; Germantown, MD) and treated with 
TURBO™ DNase (Ambion). Purity of RNA samples 
from epidermis and subcutaneous fat was confirmed by 
keratinocyte and adipose cell markers expression. Gene 
expression was assessed using semi-quantitative two-step 
RT-PCR and quantitative real-time PCR (qPCR). Reverse 
transcription was performed using 1 μg RNA, random 
hexamers and M-MLV reverse transcriptase (Invitrogen/
Life Technologies), according to manufacturer instructions 
as described [27]. The gene-specific primers were 
designed with NCBI Primer-BLAST as described [27, 
38]. qPCR with SYBR Green detection was performed on 
the LightCycler® 96 Real-Time PCR instrument (Roche 
Diagnostics, Indianapolis, IN). Each sample was tested in 
triplicate. The results were normalized to the expression of 
the housekeeping Rpl27 gene [53].
Statistical analysis
Mean and standard deviation (SD) values were 
calculated using Microsoft Excel software. The treatment 
effects in each experiment were compared by t-test using 
the GraphPad (La Jolla, CA) statistical software package. 
Differences between groups were considered significant 
at P < 0.05. All experiments were repeated 2-3 times. In 
animal experiments we used 3-4 mice per experimental 
group. In all figures, the results of one representative 
experiment are shown as means ± SD.
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